overview biotechnology medical devices healthcare services recent investments Company Description Status Stage / Year BIKAM Pharmaceuticals, Inc. Novel small molecule therapeutics for ophthalmic diseases Private Start-up / 2007* Develops novel molecular diagnostics with broad applications in infectious disease Private Start-up / 2007* Developing modified form of heparin to ameliorate cardiac ischemia-reperfusion injury following myocardial infarction Private Start-up / 2006* Novel antibiotics using patented bacterial RNA targets to treat pathogens resistant to existing drugs Private Seed / 2006* Specialty pharmaceuticals for dermatology based on proprietary drug delivery technologies Private Early / 2006* Novel anti-inflammatory agents based on endogenous mediators of inflammation resolution Private Seed / 2005* Therapeutics that target hypoxic cells to treat cancer and benign prostatic hyperplasia IPO 2005 Early / 2003 Developer of chip-based instruments and reagents for molecular diagnostics Acquired by Becton Dickinson, 2006 Early / 2002* Small molecule therapeutics for genetic disorders IPO 2007 Seed / 2002* Vaccine development Private Seed / 2002* Utilizes engineered bioassays to identify new drug candidates which regulate gene expression Private Start-up / 2002* Development and manufacture of protein microarrays Acquired by Invitrogen Corporation, 2004 Seed / 2001* Consumer focused applied genomics IPO 2005 Start-up / 2000 Antibody targeting technologies for treatment of cancer Private Early / 2000* Specialized imaging and drug delivery Private Early / 2000* Drug delivery technology for localized treatment of disease IPO 2000 Later / 1999 Computerized systems for the analysis and prediction of clinical compounds' ADME/Tox properties Acquired by ArQule, Inc., 2001 Early / 1999* Long term sustained release drug encapsulation and delivery systems Private Early / 1999* Cellular and proteomics approaches to target validation for drug development Private Seed / 1998* PolyGenomics, Inc. Genomics tools for rapid identification of molecular abnormalities affecting genes, proteins, and small molecules Merged with Molecular Staging Inc., 1999 Start-up / 1998* Novel technologies for immunodiagnostics Acquired by QIAGEN N.V., 2004 Start-up / 1998* Complement inhibition for cardiovascular and inflammatory diseases IPO 1996 Early / 1994* Khepri Pharmaceuticals Development of proteases and their inhibitors as therapeutics Acquired by Arris Pharmaceuticals, 1995 Early / 1994 Non-absorbed pharmaceuticals to eliminate target substances from the gastrointestinal tract IPO 1995 Acquired by Genzyme Corporation, 2000 Early / 1994 Leukosite, Inc. Treatment for inflammatory and autoimmune diseases IPO 1998 Acquired by Millennium Pharmaceuticals, Inc., 1999 Early / 1994 Gene Medicine Biopharmaceuticals in the fields of cardiovascular disease, oncology, and infectious diseases IPO 1994 Merged with Megabios, 1999, to create Valentis, Inc. Early / 1993 Therapeutics for diseases and disorders of the central nervous and immune systems IPO 1996 Start-up / 1993 MicroProbe Corporation, changed company name to DNA probe technologies for diagnostics and therapeutics IPO 1993 Later / 1992* Biotherapeutics for cancer treatment IPO 1997 Start-up / 1992* Prevention and treatment of cardiovascular disease IPO 1996 Early / 1992 Chiroscience Chiral pharmaceutical development IPO 1994 Merged with Celltech Group, 1999 Early / 1992 Texas Biotechnology, changed company name to Treatments for acute cardiovascular conditions IPO 1993 Early / 1991 Provider of a leading integrated platform of genomic technologies and services IPO 1993 Start-up / 1991 Chronic inflammatory disease therapeutics IPO 1991 Start-up / 1990 Autoimmune disease therapeutics IPO 1994 Early / 1989* Neurologic disorder therapeutics IPO 1989 Start-up / 1988* Wound healing agents IPO 1989 Early / 1987 Biopesticides IPO 1987 Later / 1986 Discovery and development of small molecules for cancer and immunological diseases IPO 1987 Start-up / 1986* Cambridge Biosciences Diagnostics and vaccine adjuvants IPO 1983 Merged with Bio Tech Research, 1999 Start-up / 1982* Nova Pharmaceutical Corporation Drug screening and therapy for brain tumors IPO 1983 Merged with CalBio, now Scios Inc. Start-up / 1982 Agricultural biotechnology IPO 1984 Start-up / 1981* Genetics Systems Corp Diagnostics for sexually transmitted diseases and monoclonal antibody therapeutics IPO 1981 Acquired by Bristol -Myers Squibb Company, 1985 Start-up / 1981* * Board representation at time of investment  © 2007 CHL Medical Partners. All rights reserved.